Sapablursen for erythrocytosis control in patients with polycythemia vera.

Sapablursen reduced phlebotomy frequency in phlebotomy-dependent polycythemia vera, cutting weekly rates by -0.10 in both cohort A (n=32) and cohort B (n=17).

• Why it matters: Phlebotomy-dependent polycythemia vera involves erythrocytosis and thrombosis risk, and there is a need for therapies that lessen ongoing phlebotomy burden while maintaining tolerability.
• What they did: In an ongoing phase 2a randomized, open-label IMPRSSION study, patients received sapablursen subcutaneously every 4 weeks (cohort A: 120 or 80 mg; cohort B: 40 mg), and phlebotomy frequency was tracked from baseline through weeks 17–37.
• The result: In the efficacy evaluation window, median phlebotomies fell from 5.0 at baseline (26 weeks) to 0 in cohort A and to 1.5 in cohort B, with mostly mild-to-moderate adverse events and symptom score improvement in cohort A.

AI summary of the abstract · may contain errors · not medical advice · read the paper.